EHA 2025 | Long-term follow-up with bispecific antibodies in follicular lymphoma and LBCL

I also presented like three and four year updates of both mosun and follicular and epcor and large B-cell lymphoma and obviously both these drugs are now widely used and commercially available in multiple jurisdictions around the world and the most promising thing about the updated data that we’re seeing at this meeting is that the durability of the complete responses I think that’s the main take home. For a single agent in patients with heavily pre-treated follicular and large-cell lymphoma, for mosun and epcor respectively, we are seeing quite durable complete responses. So particularly for patients who’ve attained that complete response mark, which is about 70% of patients with follicular and about 40% of patients with large B-cell lymphoma with epcor, there actually is a reasonable chance that those CRs are going to be durable. and that’s really important from counseling patients. It’s good to know in terms of planning future lines of therapy and it’s also good to know in terms of people being able to get on with their lives and being able to make plans because this is a group of patients who prior to the advent of T-cell engaging antibodies were basically very, very difficult to treat without toxic treatments like chemotherapy, stem cell transplantation and so bispecific antibodies have really been transformational in this space. And having longer follow-up on these studies gives all of us reassurance that the quality and the depth of the responses that we’ve seen are likely to continue for some time.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.